Algiax 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  laflunimus (AP-325) / Algiax
    Trial completion, Trial completion date:  AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain (clinicaltrials.gov) -  Oct 16, 2024   
    P2,  N=99, Completed, 
    Recruiting --> Completed | Trial completion date: Mar 2025 --> Oct 2024
  • ||||||||||  laflunimus (AP-325) / Algiax
    Trial completion date, Trial primary completion date:  AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain (clinicaltrials.gov) -  Jun 13, 2024   
    P2,  N=96, Recruiting, 
    Trial primary completion date: Jun 2024 --> Jan 2025 Trial completion date: Jun 2024 --> Mar 2025 | Trial primary completion date: Apr 2024 --> Jan 2025
  • ||||||||||  laflunimus (AP-325) / Algiax
    Trial completion date, Trial primary completion date:  Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients With Type 2 Diabetes (clinicaltrials.gov) -  Jan 8, 2024   
    P2,  N=38, Recruiting, 
    Trial completion date: Jun 2024 --> Mar 2025 | Trial primary completion date: Apr 2024 --> Jan 2025 Trial completion date: Sep 2022 --> Jun 2025 | Trial primary completion date: Jun 2022 --> Jun 2024
  • ||||||||||  laflunimus (AP-325) / Algiax
    Trial completion date, Trial primary completion date:  AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain (clinicaltrials.gov) -  Oct 31, 2022   
    P2,  N=96, Recruiting, 
    Trial completion date: Sep 2022 --> Jun 2025 | Trial primary completion date: Jun 2022 --> Jun 2024 Trial completion date: Apr 2023 --> Jun 2024 | Trial primary completion date: Feb 2023 --> Apr 2024
  • ||||||||||  laflunimus (AP-325) / Algiax
    Trial completion date, Trial primary completion date:  AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain (clinicaltrials.gov) -  Jan 25, 2022   
    P2,  N=96, Recruiting, 
    Trial completion date: Apr 2023 --> Jun 2024 | Trial primary completion date: Feb 2023 --> Apr 2024 Trial completion date: Feb 2022 --> Apr 2023 | Trial primary completion date: Dec 2021 --> Feb 2023
  • ||||||||||  laflunimus (AP-325) / Algiax
    Trial completion date, Trial primary completion date:  AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain (clinicaltrials.gov) -  May 20, 2021   
    P2,  N=94, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Oct 2021 --> Feb 2022 | Trial primary completion date: Aug 2021 --> Dec 2021
  • ||||||||||  laflunimus (AP-325) / Algiax
    Enrollment open:  AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain (clinicaltrials.gov) -  Aug 7, 2020   
    P2,  N=94, Recruiting, 
    Trial completion date: Oct 2021 --> Feb 2022 | Trial primary completion date: Aug 2021 --> Dec 2021 Not yet recruiting --> Recruiting